During a live event, Hans Lee, MD, and participants discussed potential approaches to modifying frontline multiple myeloma ...

Methods: Patients aged 18–75 years with transplant-eligible, previously untreated, NDMM were randomized to four 28-day cycles of lenalidomide (25 mg days 1–21) plus low-dose dexamethasone (40mg days 1 ...

Panelists discuss how recent updates from the phase 3 IsKia trial demonstrate that isatuximab combined with carfilzomib, lenalidomide, and dexamethasone improves minimal residual disease negativity ...

Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a Phase 3 study titled A RANDOMIZED, 2-ARM, ...

There was no difference in risk for lenalidomide plus cyclophosphamide, lenalidomide plus dexamethasone, and melphalan alone. "These data suggest that the future role of oral melphalan in ...

Lenalidomide offers an exciting advance in the treatment of the 5q– MDS patient. It has the ability to alter the course of MDS by inducing hematologic and cytogenetic responses, resulting in ...

Lenalidomide, an immunomodulatory agent with antiangiogenic and antineoplastic properties, is a standard treatment for initial and relapsed multiple myeloma.

A dose-adjusted lenalidomide regimen that included discontinuation of dexamethasone after 9 months appeared safe and led to similar outcomes as continuous lenalidomide plus dexamethasone among ...

1 Belada D, M.D., Ph.D., et al. A Phase 1b, Open-label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in ...